(139) Rheology-driven development of bioinks for advanced 3D-bioprinting in drug discovery

The advent of extrusion-based 3D bioprinting (EBB) has revolutionized the pharmaceutical field. 3D-printed scaffolds show superior drug screening results over traditional 2D models, potentially replacing pre-clinical animal testing¹. However, ink development complexity still limits the potential of 3D models in drug discovery. Indeed, bioinks must balance biological requirements and printability². This work aims to optimize and validate a systematic rheological approach to evaluate the rheology-to-printability relationship, enabling the development of high-performance bioinks.